ABSTRACT
A model of moderate hyperhomocysteinemia associated with mechanical injury of the musculoskeletal system was developed and experimentally substantiated. The adequacy of this model for studies of morphological and functional regularities is verified. This model can be used for the development of a new concept of evaluation of thrombotic complications of mechanical injury.
Subject(s)
Hyperhomocysteinemia/pathology , Hyperhomocysteinemia/physiopathology , Microcirculation/physiology , Animals , Disease Models, Animal , Genotype , Hyperhomocysteinemia/genetics , Male , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Methylenetetrahydrofolate Reductase (NADPH2)/metabolism , Polymorphism, Single Nucleotide/genetics , Rats , Thrombosis/genetics , Thrombosis/physiopathologyABSTRACT
We analyzed previously generated stable monocyte-derived cell line carrying mutation JAK2 V617F. Evaluation of the expression of pro- and antifibrotic factors revealed changes in the production of MMPs and their inhibitors, growth factors, galectin-3, and pentraxin 3 in cells carrying mutation JAK2 in comparison with control non-modified cells.
Subject(s)
Gene Expression Regulation , Janus Kinase 2/genetics , Mesenchymal Stem Cells/metabolism , Mutation , Blood Proteins , C-Reactive Protein/genetics , C-Reactive Protein/metabolism , Cell Communication , Coculture Techniques , Galectin 3/genetics , Galectin 3/metabolism , Galectins , Humans , Janus Kinase 2/metabolism , Matrix Metalloproteinases/genetics , Matrix Metalloproteinases/metabolism , Mesenchymal Stem Cells/cytology , Models, Biological , Primary Cell Culture , Primary Myelofibrosis/genetics , Primary Myelofibrosis/metabolism , Primary Myelofibrosis/pathology , Protein Isoforms/genetics , Protein Isoforms/metabolism , Serum Amyloid P-Component/genetics , Serum Amyloid P-Component/metabolism , Signal Transduction , THP-1 Cells , Tissue Inhibitor of Metalloproteinases/genetics , Tissue Inhibitor of Metalloproteinases/metabolismABSTRACT
Foam sclerotherapy is an innovative method of treatment for varicose disease, including its truncal forms, making it possible in outpatient conditions to achieve favourable therapeutic and cosmetic outcomes. Analysed herein are the results of foam sclerotherapy of the great saphenous vein (GSV) and its tributaries in a total of 326 patients presenting with varicose disease of lower limbs (395 GSVs) according to the improved methodology (elevation of the extremity to 60°, crural bandage, use of a cooled sclerosant solution). 6-14 days after the first session of sclerotherapy, the control ultrasound examination confirmed occlusion of the GSV in its femoral segment with no reflux in 94.9% of cases (375 GSVs). At terms from 1 year to 5 years, occlusion was diagnosed in 91.1% of cases. Besides alterations in the ultrasound image of the venous superficial bed of the limb and reduction of the trunk of the GSV and its affluents, there was positive dynamics of the clinical symptomatology of the disease.
Subject(s)
Saphenous Vein/diagnostic imaging , Sclerotherapy/methods , Ultrasonography, Doppler, Duplex/methods , Varicose Veins/therapy , Adult , Aged , Female , Follow-Up Studies , Humans , Male , Middle Aged , Retrospective Studies , Treatment Outcome , Varicose Veins/diagnostic imaging , Young AdultABSTRACT
The article is devoted to the problem of efficacy of the hepatic insufficiency (HI) prophylaxis and treatment methods in obturation jaundice. The role of energy-depending processes and the oxygen deficiency in tissues in the HI occurrence and progressing, the possibilities of medicinal correction of such disorders were studied up. The authors follow the concept of expediency of the oxygen-bearing preparations, which improve the erythrocytes function and oxygen delivery to the tissues in combination with miniinvasive decompression of bilioefferent ways, incorporation into the treatment complex of HI of mechanic genesis.
Subject(s)
Decompression, Surgical/methods , Drainage/methods , Endoscopy, Digestive System/methods , Hepatic Insufficiency/prevention & control , Jaundice, Obstructive/surgery , Blood Substitutes/administration & dosage , Fluid Therapy/methods , Fluorocarbons/administration & dosage , Hepatic Insufficiency/diagnostic imaging , Hepatic Insufficiency/etiology , Humans , Jaundice, Obstructive/complications , Jaundice, Obstructive/diagnostic imaging , Liver Function Tests , Oxygen/metabolism , Sodium Chloride/administration & dosage , Sodium Chloride/chemistry , Treatment Outcome , UltrasonographyABSTRACT
Efficacy of application of oxygen-transporting preparations in the treatment of obturation jaundice was studied. In experimental conditions while modelling obturation jaundice in animals there were revealed signs of failure of the oxygen delivery to hepatic cells, shown by significant lowering of the oxygen pressure (pO2) in hepatic tissue. To compensate such revealed disorders it is expedient to apply preparations, which owe oxygen-transporting function, such as perftoran or ozonized isotonic solution of sodium chloride. Incorporating perftoran and ozonized isotonic solution of sodium chloride in conventionally accepted complex impedes the tissue hypoxia occurrence, which starts after biliary system decompression, it promotes restoration of hepatic cells functional state in more early terms.
Subject(s)
Decompression, Surgical/methods , Disease Models, Animal , Jaundice, Obstructive/surgery , Liver/surgery , Oxygen Consumption , Animals , Female , Fluorocarbons/administration & dosage , Isotonic Solutions , Jaundice, Obstructive/metabolism , Liver/metabolism , Male , Oxygen/analysis , RabbitsABSTRACT
Efficacy of the prophylaxis and treatment methods for hepatic insufficiency in obstructive jaundice was studied. The role of an energy-dependent processes and the tissue deficit of oxygen in the hepatic insufficiency occurrence and progress, possibility of these disorders medicinal correction was delineated. The expediency of introduction of preparations, improving the erythrocytes function and the oxygen delivery to tissues in conjunction with miniinvasive biliary decompression, in therapeutic complex for hepatic insufficiency of mechanical nature was noted.
Subject(s)
Decompression, Surgical/methods , Drainage/methods , Hepatic Insufficiency/therapy , Jaundice, Obstructive/therapy , Hepatic Insufficiency/blood , Humans , Jaundice, Obstructive/blood , Liver Function Tests , Treatment OutcomeABSTRACT
Two series of efavirenz analogues have been developed: one in which the cyclopropane ring has been replaced by small heterocycles and another in which the entire acetylenic side chain has been replaced by alkyloxy groups. Several members of both series show equivalent potency to efavirenz against both wild-type virus and the key K103N mutant.
Subject(s)
Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/pharmacology , HIV Reverse Transcriptase/antagonists & inhibitors , Oxazines/chemical synthesis , Oxazines/pharmacology , Reverse Transcriptase Inhibitors/chemical synthesis , Reverse Transcriptase Inhibitors/pharmacology , Alkynes , Benzoxazines , Cyclopropanes , HIV Reverse Transcriptase/genetics , Mutation , Structure-Activity RelationshipABSTRACT
A series of 4,1-benzoxazepinone analogues of efavirenz (Sustiva) as potent NNRTIs has been discovered. The cis-3-alkylbenzoxazepinones are more potent then the trans isomers and can be synthesized preferentially by a novel stereoselective cyclization. The best compounds are potent orally bioavailable inhibitors of both wild-type HIV-1 and its clinically relevant K103N mutant virus, but are highly protein-bound in human plasma.
Subject(s)
HIV Reverse Transcriptase/antagonists & inhibitors , Oxazines/pharmacology , Reverse Transcriptase Inhibitors/pharmacology , Alkynes , Animals , Benzoxazines , Cyclopropanes , HIV Reverse Transcriptase/genetics , Humans , Macaca mulatta , Oxazines/chemistry , Oxazines/pharmacokinetics , Protein Binding , Quinazolines/chemistry , Quinazolines/pharmacokinetics , Quinazolines/pharmacology , Quinazolinones , Reverse Transcriptase Inhibitors/chemistry , Reverse Transcriptase Inhibitors/pharmacokinetics , Structure-Activity RelationshipABSTRACT
A series of 4-alkenyl and 4-alkynyl-3, 4-dihydro-4-(trifluoromethyl)-2-(1H)-quinazolinones were found to be potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) of human immunodeficiency virus type-1 (HIV-1). The 4-alkenyl-3, 4-dihydro-4-(trifluoromethyl)-2-(1H)-quinazolinones DPC 082 and DPC 083 and the 4-alkynyl-3, 4-dihydro-4-(trifluoromethyl)-2-(1H)-quinazolinones DPC 961 and DPC 963 were found to exhibit low nanomolar potency toward wild-type RF virus (IC(90) = 2.0, 2.1, 2.0, and 1.3 nM, respectively) and various single and many multiple amino acid substituted HIV-1 mutant viruses. The increased potency is combined with favorable plasma serum protein binding as demonstrated by improvements in the percent free drug in human plasma when compared to efavirenz: 3.0%, 2.0%, 1.5%, 2. 8%, and 0.2-0.5% for DPC 082, DPC 083, DPC 961, DPC 963, and efavirenz, respectively.
Subject(s)
Anti-HIV Agents/chemical synthesis , HIV Reverse Transcriptase/antagonists & inhibitors , HIV-1/drug effects , Mutation , Quinazolines/chemical synthesis , Reverse Transcriptase Inhibitors/chemical synthesis , Alkynes , Anti-HIV Agents/blood , Anti-HIV Agents/pharmacology , Benzoxazines , Blood Proteins/metabolism , Cyclopropanes , HIV-1/genetics , Humans , Molecular Structure , Oxazines/blood , Oxazines/pharmacology , Protein Binding , Quinazolines/blood , Quinazolines/pharmacology , Reverse Transcriptase Inhibitors/blood , Reverse Transcriptase Inhibitors/pharmacology , Structure-Activity Relationship , Virus Replication/drug effectsABSTRACT
Benzothiadiazine non-nucleoside reverse transcriptase inhibitors (NNRTIs) of HIV have been synthesized via a novel process to afford active inhibitors, with the most potent compound exhibiting an IC90 = 180 nM in a whole cell assay. The 2,2-dioxide-1H-2,1,3-benzothiadiazine ring system was constructed in one step from 2-amino-5-chlorobenzonitrile.
Subject(s)
Benzothiadiazines/chemical synthesis , Reverse Transcriptase Inhibitors/chemical synthesis , Benzothiadiazines/pharmacology , HIV-1/enzymology , Humans , Molecular Structure , Reverse Transcriptase Inhibitors/pharmacologyABSTRACT
A research program targeted toward the identification of expanded-spectrum nonnucleoside reverse transcriptase inhibitors which possess increased potency toward K103N-containing mutant human immunodeficiency virus (HIV) and which maintain pharmacokinetics consistent with once-a-day dosing has resulted in the identification of the 4-cyclopropylalkynyl-4-trifluoromethyl-3, 4-dihydro-2(1H)quinazolinones DPC 961 and DPC 963 and the 4-cyclopropylalkenyl-4-trifluoromethyl-3, 4-dihydro-2(1H)quinazolinones DPC 082 and DPC 083 for clinical development. DPC 961, DPC 963, DPC 082, and DPC 083 all exhibit low-nanomolar potency toward wild-type virus, K103N and L100I single-mutation variants, and many multiply amino acid-substituted HIV type 1 mutants. This high degree of potency is combined with a high degree of oral bioavailability, as demonstrated in rhesus monkeys and chimpanzees, and with plasma serum protein binding that can result in significant free levels of drug.
Subject(s)
Anti-HIV Agents/pharmacology , HIV Reverse Transcriptase/antagonists & inhibitors , HIV-1/drug effects , HIV-1/genetics , Mutation/physiology , Reverse Transcriptase Inhibitors/pharmacology , Amino Acid Substitution/genetics , Animals , Anti-HIV Agents/pharmacokinetics , Blood Proteins/metabolism , HIV-1/enzymology , Half-Life , Humans , Macaca mulatta , Male , Pan troglodytes , Protein Binding , Reverse Transcriptase Inhibitors/pharmacokinetics , StereoisomerismABSTRACT
The preparation of unsymmetrical cyclic ureas bearing novel biaryl indazoles as P2/P2' substituents was undertaken, utilizing a Suzuki coupling reaction as the key step. Compound 6i was equipotent to the lead compound of the series SE063.
Subject(s)
HIV Protease Inhibitors/chemistry , Urea/chemistry , Anti-HIV Agents/chemistry , Anti-HIV Agents/pharmacology , HIV Protease/drug effects , HIV Protease Inhibitors/pharmacology , HIV-1/enzymology , Urea/pharmacologyABSTRACT
Two series of benzoxazinones differing in the aromatic substitution pattern were prepared and evaluated as HIV-1 reverse transcriptase inhibitors. The 5-fluoro (5a-d) and 6-nitro (5e-h) substituted compounds displayed activity comparable or better than Efavirenz, the lead structure of the series.
Subject(s)
Anti-HIV Agents/chemical synthesis , Oxazines/chemistry , Oxazines/chemical synthesis , Reverse Transcriptase Inhibitors/chemical synthesis , Alkynes , Anti-HIV Agents/chemistry , Anti-HIV Agents/pharmacology , Benzoxazines , Cyclopropanes , Drug Evaluation, Preclinical , HIV Reverse Transcriptase/drug effects , Oxazines/pharmacology , Reverse Transcriptase Inhibitors/chemistry , Reverse Transcriptase Inhibitors/pharmacology , Structure-Activity RelationshipABSTRACT
Efavirenz (SUSTIVA) is a potent non-nucleoside reverse transcriptase inhibitor. Due to the observation of breakthrough mutations of the reverse transcriptase enzyme during Efavirenz therapy, we sought to develop an optimized second generation series. To that end, SAR of the substituents on the aromatic ring was undertaken and the results are summarized here. The 5,6-difluoro (4f) and the 6-methoxy (4m) substituted benzoxazinones were determined to be equipotent, and as a result such substitution patterns will be incorporated in second generation scaffolds.
Subject(s)
Anti-HIV Agents/chemical synthesis , HIV-1 , Oxazines/chemistry , Oxazines/chemical synthesis , Reverse Transcriptase Inhibitors/chemical synthesis , Alkynes , Anti-HIV Agents/pharmacology , Benzoxazines , Cyclopropanes , Molecular Structure , Oxazines/pharmacology , Reverse Transcriptase Inhibitors/pharmacology , Structure-Activity RelationshipABSTRACT
BACKGROUND: Recent clinical trials have demonstrated that HIV protease inhibitors are useful in the treatment of AIDS. It is necessary, however, to use HIV protease inhibitors in combination with other antiviral agents to inhibit the development of resistance. The daunting ability of the virus to rapidly generate resistant mutants suggests that there is an ongoing need for new HIV protease inhibitors with superior pharmacokinetic and efficacy profiles. In our attempts to design and select improved cyclic urea HIV protease inhibitors, we have simultaneously optimized potency, resistance profile, protein binding and oral bioavailability. RESULTS: We have discovered that nonsymmetrical cyclic ureas containing a 3-aminoindazole P2 group are potent inhibitors of HIV protease with excellent oral bioavailability. Furthermore, the 3-aminoindazole group forms four hydrogen bonds with the enzyme and imparts a good resistance profile. The nonsymmetrical 3-aminoindazoles DMP 850 and DMP 851 were selected as our next generation of cyclic urea HIV protease inhibitors because they achieve 8 h trough blood levels in dog, with a 10 mg/kg dose, at or above the protein-binding-adjusted IC90 value for the worst single mutant--that containing the Ile84-->Val mutation. CONCLUSIONS: In selecting our next generation of cyclic urea HIV protease inhibitors, we established a rigorous set of criteria designed to maximize chances for a sustained antiviral effect in HIV-infected individuals. As DMP 850 and DMP 851 provide plasma levels of free drug that are sufficient to inhibit wild-type HIV and several mutant forms of HIV, they could show improved ability to decrease viral load for clinically significant time periods. The ultimate success of DMP 850 and DMP 851 in clinical trials might depend on achieving or exceeding the oral bioavailability seen in dog.
Subject(s)
Anti-HIV Agents/chemical synthesis , HIV Protease Inhibitors/chemical synthesis , Urea/analogs & derivatives , Animals , Anti-HIV Agents/pharmacokinetics , Anti-HIV Agents/pharmacology , Crystallography, X-Ray , Dogs , Drug Design , HIV/drug effects , HIV/genetics , HIV/physiology , HIV Protease Inhibitors/pharmacology , Molecular Structure , Mutation , Protein Binding , Urea/chemical synthesis , Urea/chemistry , Urea/pharmacokinetics , Urea/pharmacology , Virus Replication/drug effectsABSTRACT
The mechanisms by which oxylanosterols regulate expression of hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and lower serum cholesterol levels were examined by using a novel nonmetabolizable oxylanosterol mimic, 15-oxa-32-vinyl-lanost-8-ene-3 beta, 32 diol (DMP 565). This compound, unlike other nonmetabolizable oxylanosterols, is not a substrate for lanosterol 14 alpha-methyl demethylase. Feeding rats a diet supplemented with 0.02% DMP 565 markedly decreased HMG-CoA reductase immunoreactive protein and enzyme activity levels without affecting mRNA levels. The rate of reductase protein degradation was unaffected. However, the rate of translation was reduced to less than 20% of control. Thus, DMP 565 appears to regulate hepatic HMG-CoA reductase gene expression primarily at the level of translation. The pronounced inhibition of HMG-CoA reductase by DMP 565 resulted in a compensatory increase in the functioning of the hepatic low density lipoprotein (LDL) receptor, possibly by increased cycling, as evidenced by a marked increase in the rate of degradation of the LDL receptor. The half-life of the receptor was decreased from over 7 h to only 1 h in animals receiving DMP 565. This increase in the rate of degradation occurred without a change in the steady state level of the receptor. Addition of dietary cholesterol attenuated the increased turnover of the LDL receptor. These effects on the hepatic LDL receptor have also been observed with HMG-CoA reductase inhibitors (G. C. Ness et al., 1996, Arch. Biochem, Biophys. 325, 242-248). However, the effect of DMP 565 on the rate of degradation of the hepatic LDL receptor was of a greater magnitude when equal doses of the drugs were used. These regulatory actions of DMP 565 provide, in part, an explanation for the observed hypocholesterolemic action of this compound.
Subject(s)
Anticholesteremic Agents/pharmacology , Hydroxymethylglutaryl CoA Reductases/biosynthesis , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Receptors, LDL/biosynthesis , Receptors, LDL/drug effects , Sterols/pharmacology , Administration, Oral , Animals , Enzyme Activation/drug effects , Gene Expression Regulation/drug effects , Hydroxymethylglutaryl CoA Reductases/metabolism , Lovastatin/administration & dosage , Lovastatin/pharmacology , Male , Microsomes, Liver/metabolism , Rats , Rats, Sprague-Dawley , Sterols/administration & dosageABSTRACT
Using the structural information gathered from the X-ray structures of various cyclic urea/HIVPR complexes, we designed and synthesized many nonsymmetrical P2/P2'-substituted cyclic urea analogues. Our efforts concentrated on using an indazole as one of the P2 substituents since this group imparted enzyme (Ki) potency as well as translation into excellent antiviral (IC90) potency. The second P2 substituent was used to adjust the physical and chemical properties in order to maximize oral bioavailability. Using this approach several very potent (IC90 11 nM) and orally bioavailable (F% 93-100%) compounds were discovered (21, 22). However, the resistance profiles of these compounds were inadequate, especially against the double (I84V/V82F) and ritonavir-selected mutant viruses. Further modification of the second P2 substituent in order to increase H-bonding interactions with the backbone atoms of residues Asp 29, Asp 30, and Gly 48 led to analogues with much better resistance profiles. However, these larger analogues were incompatible with the apparent molecular weight requirements for good oral bioavailability of the cyclic urea class of HIVPR inhibitors (MW < 610).
Subject(s)
Anti-HIV Agents , HIV Protease Inhibitors , Indazoles , Urea , Administration, Oral , Animals , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/chemistry , Anti-HIV Agents/pharmacology , Azepines/pharmacology , Biological Availability , Cell Line , Chromatography, High Pressure Liquid , Dogs , Drug Design , Drug Resistance, Microbial , HIV Protease Inhibitors/chemical synthesis , HIV Protease Inhibitors/chemistry , HIV Protease Inhibitors/pharmacology , HIV-1/drug effects , HIV-1/genetics , Indazoles/chemical synthesis , Indazoles/chemistry , Indazoles/pharmacology , Mutation , RNA, Viral/biosynthesis , Ritonavir/pharmacology , Structure-Activity Relationship , Transcription, Genetic , Urea/analogs & derivatives , Urea/chemical synthesis , Urea/chemistry , Urea/pharmacologyABSTRACT
26,740 blood donors and persons of high risk groups with respect to HBV infection, residing in different regions of Belarus, were examined for the presence of HBsAg in 1983-1997. Of these, 1372 persons (5.1%) were found to have HBsAg, and out of 1081 HBsAg-positive persons anti-HDV antibodies (Ab) were detected in 96 persons (8.9%). In spite of a decrease in acute virus hepatitis B morbidity and in HBsAg carriership, the occurrence of anti-HBV Ab remained stable during the period of 16 years and was equal, on the average, about 4% among asymptomatic HBsAg carriers. Patients having tuberculosis, rheumatoid arthritis, diabetes mellitus, hematological diseases, chronic hepatitides and cirrhosis of the liver were an important reservoir of HBV and HDV infections for regions with the low level of the spread of HBV. A decrease in the detection rate of anti-HDV Ab in patients with cirrhosis of the liver from 47.6% to 15.4% was noted. In 1991-1997 a decrease in the detection rate of anti-HDV Ab in patients with chronic hepatic lesions in comparison with 1983-1990 was observed, and in the age group older than 50 years this decrease was from 33.3% to 8.3%. This difference was particularly pronounces in patients with cirrhosis of the liver: 53.9% and 7.7% respectively.
Subject(s)
Blood Donors , Hepatitis D/epidemiology , Mass Screening/methods , Adolescent , Adult , Carrier State , Child , Child, Preschool , Cross-Sectional Studies , Hepatitis Antibodies/blood , Hepatitis B Surface Antigens/blood , Hepatitis Delta Virus/immunology , Humans , Infant , Infant, Newborn , Middle Aged , Prevalence , Republic of Belarus/epidemiology , Risk FactorsABSTRACT
Acyl-CoA:cholesterol acyltransferase (ACAT) is the enzyme largely responsible for intracellular cholesterol esterification. A systemic inhibitor of ACAT is believed to be able to slow or even reverse the atherosclerotic process. Towards that goal, a series of cyclic sulfides, derived from the hetero-Diels-Alder reaction of thioaldehydes with 1,3-dienes, and bearing carboxamide substituents, were prepared and evaluated for in vitro (in several tissues and species) and ex vivo ACAT inhibition. Minor changes in subsequent structure were found to have a significant effect in optimization of the biological activity of this series of compounds.
Subject(s)
Aldehydes/chemistry , Enzyme Inhibitors/chemistry , Sterol O-Acyltransferase/antagonists & inhibitors , Sulfhydryl Compounds/chemistry , Animals , Chemical Phenomena , Chemistry , Chromatography, High Pressure Liquid , Male , Microsomes, Liver/enzymology , Rats , Rats, Sprague-DawleyABSTRACT
Selected 15-, 32-, and 15,32-substituted lanosterol analogs are shown here to display time-dependent inactivation and lanosterol 14 alpha-methyl demethylase. These molecules are competitive with respect to substrate and require NADPH and O2 in order to display time dependence, thus supporting the premise that they are mechanism-based inactivators. Structural features required for lanosterol demethylation by the lanosterol demethylase such as nuclear double bond location and availability of an abstractable 15 alpha-proton are also essential elements for time-dependent inactivation. 32-(S)-Vinyllanost-8-en-3 beta,32-diol is a potent time-dependent inactivator (Kinact/Ki = 0.36 min-1 microM-1), while the 32-(R)-vinyllanost-8-en-3 beta,32-diol functions solely as a competitive demethylase inhibitor. These results support the premise that stereoselective oxidation occurs during lanosterol demethylation and that the 32-pro-S proton is abstracted during the demethylation reaction.